Managed Care Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Lifeline Biotechnologies
Grant of Chinese SDA, market launch of breast cancer detection device announced
October 9th, 2005
Lifeline Biotechnologies, Inc. (LBTN) announced that the company has been granted a registration number by the Chinese SDA (State Drug Administration), for the company's MastaScope product. This SDA registration number is comparable to the CE mark and U.S. Food and Drug Administration (FDA) 510K approvals that have already been granted for the product. The SDA registration enables the company to begin market introduction of the MastaScope in China. As a result of being granted the Chinese SDA, Lifeline reports that a significant meeting among prominent Chinese and Japanese physicians and surgeons to demonstrate and train them in the attributes and...
Source: Managed Care Law Weekly (2005-10-09)
|
